bupivacaine hydrochloride; epinephrine bitartrate
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE (bupivacaine hydrochloride; epinephrine bitartrate) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1983.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
Bupivacaine hydrochloride with epinephrine bitartrate is a long-acting local anesthetic injectable used for regional anesthesia and pain control during surgical, dental, and diagnostic procedures. It works by blocking nerve impulse generation and conduction, with epinephrine added as a vasoconstrictor to slow systemic absorption and prolong anesthetic effect, lasting up to 7 hours.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and focus on specialty/niche markets rather than expansion.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Worked on BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPositions on this product offer stability in a mature, established market with deep healthcare provider relationships, though career progression may be limited by LOE approaching status. This role suits candidates prioritizing sustainable responsibility and execution excellence over new product launches and expansion.